These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6848127)

  • 21. A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA.
    Fukue H; Anderson K; McPhedran P; Clyne L; McDonagh J
    Blood; 1992 Jan; 79(1):65-74. PubMed ID: 1370210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defective alpha-polymerization in the conversion of fibrinogen Baltimore to fibrin.
    Brown CH; Crowe MF
    J Clin Invest; 1975 Jun; 55(6):1190-4. PubMed ID: 1133167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymerization properties of two normally circulating fibrinogens, HMW and LMW. Evidence that the COOH-terminal end of the a-chain is of importance for fibrin polymerization.
    Holm B; Brosstad F; Kierulf P; Godal HC
    Thromb Res; 1985 Sep; 39(5):595-606. PubMed ID: 4082102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.
    Greenberg CS; Miraglia CC; Rickles FR; Shuman MA
    J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release.
    Galanakis DK; Neerman-Arbez M; Scheiner T; Henschen A; Hubbs D; Nagaswami C; Weisel JW
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):731-7. PubMed ID: 17982313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Citrullinated fibrinogen shows defects in FPA and FPB release and fibrin polymerization catalyzed by thrombin.
    Okumura N; Haneishi A; Terasawa F
    Clin Chim Acta; 2009 Mar; 401(1-2):119-23. PubMed ID: 19109936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder.
    Colwell NS; Tollefsen DM; Blinder MA
    Br J Haematol; 1997 Apr; 97(1):219-26. PubMed ID: 9136969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrinogen Marburg a new genetic variant of fibrinogen.
    Fuchs G; Egbring R; Havemann K
    Blut; 1977 Feb; 34(2):107-18. PubMed ID: 836966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinogen Chapel Hill II: defective in reactions with thrombin, factor XIIIa and plasmin.
    Carrell N; McDonagh J
    Br J Haematol; 1982 Sep; 52(1):35-47. PubMed ID: 6126210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A.
    Crum ED; Shainoff JR; Graham RC; Ratnoff OD
    J Clin Invest; 1974 May; 53(5):1308-19. PubMed ID: 4856883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of the fibrinolytic process in a patient with antiphospholipid syndrome.
    Marchi R; Garmendia J; Kanzler D; Fuenmayor J
    Blood Coagul Fibrinolysis; 2015 Apr; 26(3):239-45. PubMed ID: 24418942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modification of fibrin network ultrastructure by Fab fragments specific for different domain of fibrinogen.
    Cierniewski CS; Janiak A; Wyroba E
    Acta Biochim Pol; 1986; 33(3):195-202. PubMed ID: 2433859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system.
    Lorand L; Velasco PT; Rinne JR; Amare M; Miller LK; Zucker ML
    Proc Natl Acad Sci U S A; 1988 Jan; 85(1):232-6. PubMed ID: 3422419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired dysfibrinogenemia in a hemophiliac with hepatoma: resolution of fibrinogen dysfunction following chemotherapy.
    Ballard JO; Kelly GA; Kukrika MD; Sanders JC; Eyster ME
    Cancer; 1981 Aug; 48(3):686-90. PubMed ID: 6265056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.
    Gralnick HR; Givelber HM; Shainoff JR; Finlayson JS
    J Clin Invest; 1971 Sep; 50(9):1819-30. PubMed ID: 5564389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrin polymerization defect in HIV-infected patients--evidence for a critical role of albumin in the prolongation of thrombin and reptilase clotting times.
    Toulon P; Frere E; Bachmeyer C; Candia N; Blanche P; Sereni D; Sicard D
    Thromb Haemost; 1995 Mar; 73(3):349-55. PubMed ID: 7667815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.
    Matsuda M; Baba M; Morimoto K; Nakamikawa C
    J Clin Invest; 1983 Sep; 72(3):1034-41. PubMed ID: 6886002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A hereditary dysfibrinogenemia: fibrinogen Awaji.
    Matsuo T; Okuno S; Mukaida T; Ueshima S; Okada K; Matsuo O
    Haemostasis; 1987; 17(1-2):89-97. PubMed ID: 3596361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of fibrin polymerization by fragment d is affected by calcium, Gly-Pro-Arg and Gly-His-Arg.
    Furlan M; Rupp C; Beck EA
    Biochim Biophys Acta; 1983 Jan; 742(1):25-32. PubMed ID: 6824684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Increased thrombin time in a patient with multiple myeloma].
    Bohler A; Redondo M; Lämmle B
    Ther Umsch; 1999 Sep; 56(9):491-4. PubMed ID: 10517116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.